Crystal entecavir, crystal entecavir formulation and methods for the preparation thereof
US9408849B2 · kind B2 · utility
0Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 4, 2014 |
| Grant date | Aug 9, 2016 |
| Priority date | — |
| Expiry date | Apr 4, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a pharmaceutical composition for treating hepatitis B virus infection comprising crystalline entecavir as the pharmaceutically active ingredient and one or more pharmaceutically acceptable excipients. The tablet and capsule of the pharmaceutical composition have improved stability compared to that of amorphous entecavir under the conditions of light, high temperature and high humidity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.